olivLaw · European equity research
Roquefort Therapeutics plc COIL.L
United Kingdom · London Stock Exchange · ISIN GB00BSHRN331 · Vertical: Listed companies from United Kingdom
Roquefort Therapeutics plc is a UK biotechnology company developing antibody, siRNA and cell therapy programmes through subsidiaries licensed from partners in Australia and the UK. The company remains pre-revenue, with significant operating losses, and the value of its assets depends largely on its investments in subsidiaries and its ability to raise further funds or secure licensing deals.
At the close of 05 Nov 2026, Roquefort Therapeutics plc (COIL.L) stock was 0.07 GBP (+0.00% on the day), with beta -0.71, 52-week range 0.01–0.27 GBP.
Data as of · AI analysis dated · Source: ESEF annual reports and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 40.1
- weak (30–45)
- Bollinger (20, 2)
- 0.06 – 0.07
- in the upper half of the band · %B 0.56 · band width 12.0%
- SMA 50 / 200
- 0.08 / 0.12
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.00 / -0.00
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | EURO STOXX 50 | vs EURO STOXX 50 | Vertical median | |
|---|---|---|---|---|
| 1 month | +4.5% | −0.6% | +5.2 pp | — |
| 3 months | −29.2% | −4.2% | −25.1 pp | — |
| 6 months | unavailable | +4.3% | unavailable | — |
| Year to date | −44.8% | +7.5% | −52.3 pp | — |
| 1 year | −55.5% | +9.9% | −65.4 pp | +5.8% |
| 3 years | −90.1% | +49.8% | −140.0 pp | +26.3% |
| 5 years | unavailable | +42.8% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
EPS unavailable in the issuer's structured filings (e.g. a partnership reports per unit, not per share).
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 0 | 200.0 k | 0 |
| Revenue YoY | unavailable | unavailable | −100.0% |
| Net income | -1.6 m | -1.7 m | -971.8 k |
| Net income YoY | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | unavailable |
| Diluted EPS YoY | unavailable | unavailable | unavailable |
| net % | unavailable | -872.3% | unavailable |
| Free cash flow | -1.6 m | -1.8 m | -783.7 k |
Balance sheet & financial health
Fiscal year 2024 · 31 Dec 2024
- Cash
- 337.1 k GBP
- Financial debt
- 400.1 k GBP
- Net debt
- 63.0 k GBP
- Equity
- 4.9 m GBP
- Total assets
- 5.8 m GBP
- Debt / equity
- 0.08x
- Current ratio
- unavailable
- ROE
- -18.7%
- ROA
- -16.4%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (GBP)
Income statement · GBP
| Line | 2022 | 2023 | 2024 | Source (latest year) |
|---|---|---|---|---|
| Revenue | 0 | 200.0 k | 0 | esef· 20 May 2025verified |
| Cost of revenue | — | 0 | 16.0 k | esef· 20 May 2025verified |
| Gross profit | — | 200.0 k ≈ | -16.0 k ≈ | esef· 20 May 2025derived |
| Research & development | 319.3 k | 620.2 k | 152.9 k | esef· 20 May 2025verified |
| Interest expense | — | 0 | 52.8 k | esef· 20 May 2025verified |
| Pre-tax income | -1.6 m | -1.9 m | -1.2 m | esef· 20 May 2025verified |
| Income tax | -18.9 k | -187.7 k | -242.8 k | esef· 20 May 2025verified |
| Net income | -1.6 m | -1.7 m | -971.8 k | esef· 20 May 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue.
Balance sheet · GBP
| Line | 2022 | 2023 | 2024 | Source (latest year) |
|---|---|---|---|---|
| Cash | 2.3 m | 537.3 k | 337.1 k | esef· 20 May 2025verified |
| Receivables | 101.7 k | 157.6 k | 25.4 k | esef· 20 May 2025verified |
| Current assets | 2.4 m | 694.9 k | 362.5 k | esef· 20 May 2025verified |
| Property, plant & equipment, net | 0 | 50.2 k | 44.7 k | esef· 20 May 2025verified |
| Total assets | 7.8 m | 6.1 m | 5.8 m | esef· 20 May 2025verified |
| Short-term debt | — | 0 | 400.1 k | esef· 20 May 2025verified |
| Total liabilities | 561.6 k | 589.0 k | 861.7 k | esef· 20 May 2025verified |
| Equity | 7.2 m | 5.5 m | 4.9 m | esef· 20 May 2025verified |
Cash flow · GBP
| Line | 2022 | 2023 | 2024 | Source (latest year) |
|---|---|---|---|---|
| Operating cash flow | -1.6 m | -1.7 m | -783.7 k | esef· 20 May 2025verified |
| Capex | 0 | 54.0 k | 0 | esef· 20 May 2025verified |
| Free cash flow | -1.6 m ≈ | -1.8 m ≈ | -783.7 k ≈ | esef· 20 May 2025derived |
| Investing cash flow | -103.5 k | -52.6 k | 0 | esef· 20 May 2025verified |
| Financing cash flow | 3.1 m | -58 | 584.9 k | esef· 20 May 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 0 of at least 6
- score weight coverage: 0.0% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: unavailable
Key indicators
Coverage and freshness
The data is older than the freshness threshold.
Score by group
0% · Insufficient data
Estimated value range
unavailable — no valuation assumptions for the reporting currency
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
Assumptions (illustrative, editorial)
- Risk-free rate
- 6.5%
- Equity risk premium
- 6.0%
- Beta (default)
- 1.00
- Cost of equity
- 12.5%
- Terminal growth
- 3.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 0 of at least 6; score weight coverage: 0.0% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | unavailable | unavailable | — |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partialunavailable · 0/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partialunavailable · 0/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Roquefort Therapeutics PLC (COIL.L). Latest full fiscal year: 2024; data up to 2024-12-31.
Figures computed from the financial statements: revenue 0 GBP in 2024; YoY growth -100.0%; ROE -18.7%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 0 of at least 6; score weight coverage: 0.0% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
What contradicts it
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
Not assessed (insufficient data or a ratio without meaning): ROIC, Net margin, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, Current ratio, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Listed companies from United Kingdom · same country · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| BATS.LBritish American Tobacco P.L.C. | 104.3 bn | 13.5 | 16.5% | 30.3% | −1.0% | +7% / +88% |
| ABF.LAssociated British Foods PLC | 14.7 bn | 14.3 | 9.2% | 5.3% | −3.1% | −5% / −15% |
| 0EV1.LCarnival PLC | 5.5 bn | 4.1 | 46.7% | 13.4% | +6.4% | unavailable / unavailable |
| BAB.LBabcock International Group PLC | 5.1 bn | 24.7 | 34.7% | 4.1% | +7.2% | −10% / +158% |
| AUTO.LAutotrader Group PLC | 4.8 bn | 16.4 | 60.2% | 47.1% | +3.9% | −13% / −23% |
| BBY.LBalfour Beatty PLC | 4.2 bn | 16.3 | 23.2% | 2.8% | +15.2% | +20% / +160% |
| ABDN.LAberdeen Group PLC | 4.1 bn | 10.8 | 8.0% | 28.9% | −2.1% | +11% / +41% |
| BKG.LThe Berkeley Group Holdings PLC | 3.6 bn | 11.3 | 8.8% | 13.4% | −4.2% | −0% / −22% |
| BME.LB&M European Value Retail PLC | 2.9 bn | 17.4 | 21.2% | 2.8% | +3.7% | +68% / −51% |
| AJB.LAj Bell PLC | 2.4 bn | 22.8 | 49.9% | 33.1% | +18.0% | +8% / +128% |
| ASHM.LAshmore Group PLC | 1.4 bn | 13.9 | 13.1% | 71.6% | −0.1% | +28% / +18% |
| BCG.LBaltic Classifieds Group PLC | 1.2 bn | 23.2 | 15.8% | 57.6% | +6.9% | −99% / −99% |
| APN.LApplied Nutrition PLC | 763.6 m | 36.2 | 41.2% | 19.7% | +24.2% | +71% / unavailable |
| BAG.LA.G. Barr P.L.C. | 671.9 m | 14.4 | 14.4% | 10.8% | +4.0% | −7% / +26% |
| ASC.LAsos PLC | 494.5 m | — | -81.3% | -12.0% | −14.7% | +71% / +8% |
| ALFA.LAlfa Financial Software Holdings PLC | 486.8 m | 16.3 | 61.5% | 23.8% | +15.3% | −28% / +10% |
| AML.LAston Martin Lagonda Global Holdings PLC | 344.3 m | — | -93.4% | -39.2% | −20.6% | −45% / −85% |
| APTD.LAptitude Software Group PLC | 111.3 m | 28.5 | 7.2% | 6.2% | −7.3% | −30% / −23% |
| AMGO.LAmigo Holdings PLC | 9.9 m | — | — | — | −81.9% | +325% / +844% |
| ASBE.LAssociated British Engineering PLC | 605.3 k | — | -19.1% | — | unavailable | unavailable / unavailable |
| AMIF.LAmicorp Fs (uk) PLC | 221.6 k | 0.1 | 27.5% | 9.1% | +8.1% | unavailable / unavailable |
| AAF.LAirtel Africa PLC | — | — | 24.1% | 10.6% | +29.5% | −7% / +164% |
| AAL.LAnglo American PLC | — | — | -19.3% | -20.2% | +4.5% | +30% / +76% |
| ACG.LAcg Metals Limited | — | — | -80.3% | -32.0% | +134.8% | +60% / +63% |
| AEP.LAnglo-Eastern Plantations PLC | — | — | 16.1% | 19.5% | +25.0% | +5% / +113% |
1- and 3-year price returns: for COIL.L from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Roquefort Therapeutics plc is a UK biotechnology company developing antibody, siRNA and cell therapy programmes through subsidiaries licensed from partners in Australia and the UK. The company remains pre-revenue, with significant operating losses, and the value of its assets depends largely on its investments in subsidiaries and its ability to raise further funds or secure licensing deals 1.
SWOT
Strengths
Weaknesses
Opportunities
Risks
- No significant revenuehigh
The company has no significant revenue and there is no guarantee it will generate significant revenue in the near future 1.
- Technical and clinical riskhigh
Research programmes may face technical failures or unfavourable clinical results, and an approved product is not assured 1.
- Dependence on licenceshigh
Patent rights could be forfeited if either party fails to meet licence conditions 1.
- Further fundingmedium
Future operations depend on raising funds through equity markets or licensing revenue deals 1.
- Leadership changesmedium
Departures from management and the board could affect strategy execution and the expertise required 1.
Investment thesis
What would need to be true (bull case)
- If a programme reaches a successful licensing stage, the company could attract funding without relying solely on new share issues 1.
- A portfolio of worldwide licences across several therapeutic platforms could offer multiple entry points for negotiations 1.
- Board experience in capital markets and biotechnology could help manage funding stages 1.
What would break the thesis
- Without significant revenue, the company could remain reliant on new share issues, with dilution as a consequence 1.
- Technical and regulatory risks could prevent programmes from reaching approval, leaving assets without realisable value 1.
- Leadership changes in 2025 could slow programme execution and licensing negotiations 1.
What to watch
- Announcements of licensing agreements or partnerships2025
- Cash position and funding requirementsQ1 2025
- Appointment of a permanent chief executive2025
- Progress of research programmes and licencesnext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Roquefort Therapeutics plc is the group holding Lyramid Pty Ltd and Oncogeni Ltd, subsidiaries that are wholly owned 1. Lyramid runs Midkine antibody research under a worldwide licence with Anagenics Ltd, while Oncogeni operates its MK Cell and siRNA programmes under licences with Cell Therapy Limited and Sirna Limited 1. The company has not generated significant revenue and expenses its research and development as programmes progress.
Management changed in March 2025, when the chief executive and executive director resigned and an interim managing director was appointed, making near-term funding and strategy points to watch 1.
Segments
Midkine programmes (Lyramid)
Lyramid Pty Ltd runs antibody research and development against Midkine under a worldwide licence with Anagenics Ltd, the owner of the patents 1.
MK Cell and siRNA programmes (Oncogeni)
Oncogeni Ltd develops its MK Cell and siRNA programmes under worldwide licences with Cell Therapy Limited and Sirna Limited respectively 1.
Revenue and operations
Revenue was 200000 pounds sterling in fiscal 2023 and nil in 2024, showing the commercial side is still at an early stage 1.
Market context
The company operates in therapeutic biotechnology, where programmes pass through long clinical and regulatory stages with high failure rates. The report notes that very few drugs make it from discovery to approval, and the market for new drug classes could become too competitive 1. Market capitalisation is not analysed here because it depends on the share price.
For an issuer with almost no revenue, access to capital markets and licensing deals remains the key factor for continuing operations 1.
Trends
- Strict regulatory requirementsheadwind
Biotechnology programmes face the most stringent oversight from government agencies and ethics committees, which could delay approvals 1.
- Intellectual property protectionmixed
Patents and licences are essential, and filing them in all countries is costly; rights could be lost if a party fails to meet licence conditions 1.
- Access to capital marketsheadwind
Pre-revenue companies depend on their ability to raise funds through capital markets or licensing deals 1.
- Licensing dealstailwind
If the group secures valuable licensing agreements, it could reduce its reliance on share issues for funding 1.
Competitive position
The report warns that other companies are developing effective treatments for the same conditions, which could make commercialisation harder 1. The supplied sources do not identify US-listed competitors.
- Anagenics Ltd
Owns the Midkine patents that Lyramid licenses; the relationship is licensing rather than direct competition 1.
- Cell Therapy Limited
Licensing partner for Oncogeni's MK Cell programme 1.
- Sirna Limited
Licensing partner for Oncogeni's siRNA programme 1.
- Other companies in the same therapeutic areas
The source mentions companies developing treatments for the same conditions without naming them 1.
News & filings
In the press
No news in our archive over the last 180 days.
Annual reports (ESEF)
- Annual report 202420 May 2025
- Annual report 202302 May 2024
Sources
- [1] Annual report, fiscal year ended 2024-12-31 (ESEF) · SEC / Roquefort Therapeutics plc · 31 Dec 2024
Figures computed by olivLaw from ESEF annual reports and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.